INTRODUCTION AND OBJECTIVES: Red patches in the bladder are often seen during endoscopic surveillance of bladder cancer at cystoscopy, particularly in patients who have had intravesical BCG treatment. However, it is difficult to distinguish BCG artefact from malignancy, namely carcinoma in-situ (CIS) in the absence of narrow band imaging or photodynamic diagnostics. Therefore, can we safely assume that histologically benign persistent red patches biopsied previously within a certain timeframe will remain benign entities? Our objectives are to establish whether the regular biopsy of red patches seen during endoscopic surveillance for bladder cancer is worthwhile and determine a suitable time frame for repeat biopsy of prior histologically benign persistent red patches in patients on endoscopic surveillance for bladder cancer.
METHODS: 4,805 flexible cystoscopy (FC) reports over a 12-month period (January -December 2015) were retrospectively reviewed at a UK tertiary teaching hospital and those undergoing cystoscopic surveillance for bladder cancer and found to have solitary red patches at flexible cystoscopy were included in the study. A proportion of these cases had biopsies taken which underwent histopathological analysis.
RESULTS: 241 flexible cystoscopies performed on 183 patients on endoscopic surveillance for bladder cancer had red patches and of these, 120 (49.8%) had a history of intravesical BCG therapy. Eightyfive patients (35.3%) underwent biopsy of the red patch. Malignancy was found in 20 biopsies (23.5%), of which, 11 out of 20 (55%) were CIS. Sixteen of these recurrences had been biopsied previously of which 11 (68.8%) were benign at last biopsy, 6 of which in the last 12 months. The remaining four recurrences had no previous biopsy. Eleven out of sixteen (68.8%) of recurrences were found in patients who had been biopsied within the last 12 months. No cases of malignancy were identified in patients with low-risk bladder cancer.
CONCLUSIONS: We recommend the biopsy of all red patches found during endoscopic surveillance of patients with intermediate/high risk bladder cancer due to the significant incidence of malignant recurrence identified, particularly if no biopsy has been performed within the previous 12 months due to the high yield of malignant recurrence identified. This is independent of previous biopsy histology.
Source of Funding: None.
MP10-07 INCREASED RISK OF BLADDER CANCER IN CHRONIC KIDNEY DISEASE PATIENTS WITH RENAL TRANSPLANTATION
Min-Che Tung*, Kuan-Chun Hsueh, Taichung, Taiwan; Kuan-Hua Huang, Tainan, Taiwan; Chiao-Ling Chen, YUAN-HUNG WANG, Chia-Chang Wu, New Taipei City, Taiwan INTRODUCTION AND OBJECTIVES: Chronic kidney disease (CKD) patients without effective treatment and follow-up usually progressed to end-stage renal disease (ESRD). Various therapeutic modalities including hemodialysis, peritoneal dialysis and renal transplantation are usually used to treat CKD patients. However, whether various therapeutic modalities can modify the risk of chronic diseases such as malignancies in CKD patients remains unclear. Therefore, the present study aims to investigate the association between therapeutic modalities of CKD patients and chronic diseases in Taiwan. METHODS: The National Health Insurance program was implemented since March 1995 by the National Health Insurance Administration, Ministry of Health and Welfare, with a coverage over e110 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 99% of 23 million people in Taiwan. The National Health Insurance Research Database (NHIRD) was released for research purposes. A total of 868 CKD patients who received renal transplantation (RT) and 54,243 non-CKD controls matched for age, gender and index date were recruited from the NHIRD. The CKD patients with RT was also confirmed by the registry of catastrophic illness. The cancer incidence was identified through cross-referencing with the Cancer Registry Database. Risks were estimated as hazard ratios (HRs) and their 95% confidence intervals (CIs) by using a Cox proportional hazards model. RESULTS: For CKD patients with RT, a significant higher incidence rate ratio (IRR) of all cancer sites (IRR ¼ 3.79, 95% CI ¼ 3.12-4.62) was found. After the adjustment for age, sex and co-morbidities, we also observed a significantly increased cancer risk of 3.87 (HR ¼ 3.79, 95% CI ¼ 3.16-4.73). Especially, we found that CKD patients with RT have a significant increased IRR of bladder cancer (IRR ¼ 14.42, 95% CI ¼ 8.09-25.67). A greatly increased bladder cancer risk (HR ¼ 17.67, 95% CI ¼ 9.64-32.38) was found for CKD patients with RT after the adjustment for age, sex and co-morbidities.
CONCLUSIONS: CKD patients have a higher risk of subsequent cancers, but the effect of therapeutic modalities such as RT on cancer risk is still unclear. Our finding is that CKD patients with RT have a significant increased risk of bladder cancer. Therefore, we should pay more attention to carry out effective treatments and implement an intensive follow-up to prevent CKD patients to progress to cancer.
Source of Funding:
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MP10-08 A PANEL OF MICRO-RNA SIGNATURE AS A TOOL FOR PREDICTING SURVIVAL OF PATIENTS WITH UROTHELIAL CARCINOMA OF THE BLADDER
Teruo Inamoto*, Kiyoshi Takahara, Naokazu Ibuki, Tomoaki Takai, Taizo Uchimoto, Kenkichi Saito, Naoki Tanda, Yuki Yoshikawa, Koichiro Minami, Hajime Hirano, Hayahito Nomi, Haruhito Azuma, Takatsuki, Japan INTRODUCTION AND OBJECTIVES: Micro-RNA (miRNA) expression is altered in urologic malignancies, including urothelial carcinoma of the bladder (UCB). Individual miRs have been shown to modulate multiple signaling pathways that contribute to BC. To identify a panel of miRNA signature that can predict aggressive phenotype from normal non-aggressive counterpart using miRNA expression levels, and to assess the prognostic value of this specific miRNA markers in patients with UBC.
METHODS: To determine candidate miRNAs as prognostic biomarkers for dividing aggressive type of UBC, miRNA expression was profiled in patients 0 samples with an aggressive phenotype or nonaggressive phenotype using 3D-Gene miRNA labeling kit (Toray, JAPAN). To create a prognostic index model, we used the panel of 9-miRNAs signature based on Cancer Genome Atlas (TCGA) data portal [TCGA Data Portal [https://tcga data.nci.nih.gov/tcga/tcgaHome2.jsp]]. MiRNA expression data and corresponding clinical data, including outcome and staging information of 84 UBC patients were obtained. The Kaplan-Meier and log-rank test were performed to quantify the survival functions in two groups.
RESULTS: Deregulation of nine miRNAs (hsa-miR-99a-5p, hsa-miR-100-5p, hsa-miR-125b-5p, hsa-miR-145-5p, hsa-miR-4324, hsa-miR-34b-5p, hsa-miR-29c-3p, hsa-miR-135a-3p, hsa-miR-33b-3p) was determined in a UBC patients with aggressive phenotype compared with non-aggressive subject. To validate the prognostic power of the nine-signature miRNAs using the TCGA dataset of bladder cancer, the survival status and tumor miRNA expression of all 84 TCGA BCa patients, ranked according to the prognostic score values. Of nine miRNAs, six were associated with high risk (hsa-miR-99a-5p, hsa-miR-100-5p, hsa-miR-125b-5p, hsa-miR-4324, hsa-miR-34b-5p, and hsamiR-135a-3p) and three were shown to be protective (hsa-miR-145-5p, hsa-miR-29c-3p, and hsa-miR-33b-3p METHODS: This study examined the intravesical recurrent rate among men treated with or without AST by androgen-deprivation therapy for prostate cancer or 5a-reductase inhibitor dutasteride for benign prostatic hyperplasia.
RESULTS: This study included 228 men with AST (n ¼ 32) or without AST (n ¼ 196) . During the median follow-up period of 3.6 or 3.0 years, intravesical recurrence occurred in four (12.5%) or 59 (30.1%) of men with or without AST, respectively. On multivariate analysis, multiple tumor (hazard ration, HR ¼ 1.82, p ¼ 0.027), large tumor (HR ¼ 2.13, p ¼ 0.043) and ever smoking (HR ¼ 2.45, p ¼ 0.020) as well as the presence of AST (HR ¼ 0.36, p ¼ 0.024) were independent risk factors for intravesical recurrence (Fig. A) . Notably, tumor progression to muscle-invasive bladder cancer occurred in six (3.1%) men without AST, while no case progressed to muscle-invasive bladder cancer in men with AST.
CONCLUSIONS: Our study suggested the possibility of AST for prophylactic use of intravesical recurrence of bladder cancer. Further explorations on the prophylactic effect of AST on bladder cancer pathogenesis are warranted.
